Education
About Us
Working with TipRanks
Follow Us
Vor Biopharma (VOR)
NASDAQ:VOR
VOR Stock Chart & Stats
$9.12
<$0.01(<0.01%)
At close: 4:00 PM EST
$9.12
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$2.63 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)753.62K
Market Cap
$204.51M
Enterprise Value$158.13M
Total Cash (Recent Filing)$170.46M
Total Debt (Recent Filing)$3.06M
Price to Earnings (P/E)―
Beta4.81
Next Earnings
Mar 19, 2026EPS Estimate
-1.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-121.63
Shares Outstanding20,410,630
10 Day Avg. Volume1,436,605
30 Day Avg. Volume753,622
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.76
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-93.57
Enterprise Value/Ebitda-0.14
Forecast
1Y Price Target
$50.33Price Target Upside451.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-380.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Product DevelopmentTelitacicept has achieved multiple regulatory approvals and treated over 70,000 patients, suggesting potential for success in larger global markets.
Funding And Financial StabilityVor Bio reported cash, cash equivalents, and marketable securities sufficient to fund operations into 1Q27.
Leadership And ManagementRecent executive-level additions, particularly the hiring of a Chief Development Officer with a successful track record, have bolstered confidence in the leadership team's ability to execute a strategy for long-term value creation.
Bears Say
Competitive LandscapeThe competitive landscape is increasingly dense with several competitor molecules, highlighting challenges in establishing clinical differentiation.
Funding ChallengesVor would likely need to raise capital to have sufficient runway to conduct the anticipated global Phase 3 study in SjD.
Stock Price And Market ReactionVor shares declined sharply as the offer price of $10.00 was a ~47% discount to the prior closing price, $18.80.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma’s price range in the past 12 months?
Vor Biopharma lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma’s market cap?
Vor Biopharma’s market cap is $204.51M.
When is Vor Biopharma’s upcoming earnings report date?
Vor Biopharma’s upcoming earnings report date is Mar 19, 2026 which is in 119 days.
How were Vor Biopharma’s earnings last quarter?
Vor Biopharma released its earnings results on Nov 13, 2025. The company reported -$121.63 earnings per share for the quarter, missing the consensus estimate of -$3.452 by -$118.178.
Is Vor Biopharma overvalued?
According to Wall Street analysts Vor Biopharma’s price is currently Undervalued.
Does Vor Biopharma pay dividends?
Vor Biopharma does not currently pay dividends.
What is Vor Biopharma’s EPS estimate?
Vor Biopharma’s EPS estimate is -1.9.
How many shares outstanding does Vor Biopharma have?
Vor Biopharma has 20,410,630 shares outstanding.
What happened to Vor Biopharma’s price movement after its last earnings report?
Vor Biopharma reported an EPS of -$121.63 in its last earnings report, missing expectations of -$3.452. Following the earnings report the stock price went up 2.667%.
Which hedge fund is a major shareholder of Vor Biopharma?
Currently, no hedge funds are holding shares in VOR
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.33 (451.86% Upside)
$50.33 (451.86% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $61.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 3.5%
Last 30 Days ▼ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.64%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
51.94%
Trailing 12-Months
Company Description
Vor Biopharma
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$50.33
▲(451.86% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---